Who is sponsoring NCT04142086?

NCT04142086 is sponsored by Sanofi Pasteur, a Sanofi Company.

What condition does NCT04142086 study?

NCT04142086 studies Yellow Fever (Healthy Volunteers).

Is NCT04142086 still recruiting?

NCT04142086 is currently completed. Last updated 22 September 2025.

Last reviewed 2025-09-22 · How we verify

NCT04142086: VYF01

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults

Completed Phase 1 Last updated 22 September 2025

What this trial tests

Phase 1 trial testing Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine in Yellow Fever (Healthy Volunteers) in 73 participants. Completed in 24 June 2021.

Timeline

15 January 2020

Primary endpoint
24 June 2021

24 June 2021

Quick facts

Lead sponsor	Sanofi Pasteur, a Sanofi Company
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	73
Start date	15 January 2020
Primary completion	24 June 2021
Estimated completion	24 June 2021
Sites	1 location across United States

Drugs / interventions tested

Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine — full drug profile →
Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine — full drug profile →
Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine — full drug profile →
Yellow fever vaccine — full drug profile →

Conditions studied

Yellow Fever (Healthy Volunteers) — all drugs for Yellow Fever (Healthy Volunteers) →

Sponsor

Sanofi Pasteur, a Sanofi Company — full company profile →

Who can join

Adults 18 to 60, any sex, with Yellow Fever (Healthy Volunteers). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objectives of the study are: * To describe the safety profile of each of the 3 dosages of vYF and of YF-VAX® within the 28 days post-vaccination and up to the 6 months (Day 180) post-vaccination visit * To describe the antibody responses elicited by each of the 3 dosages of vYF and by YF-VAX on Day 0 pre-vaccination and then on Day 10, Day 14, Day 28 and 6 months (Day 180) post-vaccination overall and by baseline flavivirus serostatus * To quantify the detectable yellow fever (YF) vaccinal viremia in each vaccine groups (vYF and YF-VAX) in a subset of subjects on Day 0 visit, Day 1 visit, Day 3 visit, Day 5 visit, Day 7 visit, Day 10 visit, and Day 14 visit.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

The Present and Future of Yellow Fever Vaccines.
Hansen CA, Barrett ADT. · · 2021 · cited 49× · PMID 34577591 · DOI 10.3390/ph14090891
A Yellow Fever Virus 17D Infection and Disease Mouse Model Used to Evaluate a Chimeric Binjari-Yellow Fever Virus Vaccine.
Yan K, Vet LJ, Tang B, Hobson-Peters J, et al · · 2020 · cited 39× · PMID 32660106 · DOI 10.3390/vaccines8030368
Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
Piras-Douce F, Raynal F, Raquin A, Girerd-Chambaz Y, et al · · 2021 · cited 18× · PMID 33685778 · DOI 10.1016/j.vaccine.2021.02.033
Next generation yellow fever vaccine induces an equivalent immune and transcriptomic profile to the current vaccine: observations from a phase I randomised clinical trial.
Pagnon A, Carre C, Aguirre M, Chautard E, et al · · 2024 · PMID 39293214 · DOI 10.1016/j.ebiom.2024.105332

Verify or expand the search:

Other Sanofi Pasteur, a Sanofi Company trials

Trials by the same sponsor.

NCT07536048 — A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years · not yet recruiting
NCT07222059 — Phase 3 Single Arm, Open Study on vYF in Adults · Phase 3 · completed
NCT07013747 — Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne · Phase 1, PHASE2 · recruiting
NCT06838000 — Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) i · Phase 3 · active not recruiting
NCT06793826 — Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04142086 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sanofi Pasteur, a Sanofi Company
Last refreshed: 22 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04142086.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing